title: [Transfer factor effectiveness patients with persistent genital human papillomavirus infection].
abstract: BACKGROUND
  Human papillomavirus (HPV) is one of the most common sexually transmitted infections worldwide. Most HPV infections are cleared within two years by the immune system. Only in 5% to 10% of infected women the infection persists determining a high risk of developing cervical intraepithelial neoplasia. The transfer factor (TF) or dialyzable leukocyte extract is an immunomodulator that has been successfully used as an adjuvant in the treatment of intracelular infections such as recurrent herpes virus diseases.
  
  
  METHODS
  One daily dose of transfer factor was given for five days and subsequently each week for five weeks to a group of women with persistent genital papillomavirus infection.
  
  
  RESULTS
  We included 13 patients, aged 19 to 45 years, with first intercourse between the ages of 14 to 23, and a mean of three sexual partners in their lifetime. All of them had persistent HPV that had been treated before with local and ablative therapeutic options, including cervical freezing, cervical conization, cauterizing loop, imiquimod and podophyllin. Transfer factor was administered daily for 5 days, and subsequently at 7-day intervals for 5 weeks. We found a clinical significant improvement in the gynaecological evaluation of cervical, vaginal, vulvar and perineal lesions. No recurrences have developed for at least 1 year of follow-up.
  
  
  CONCLUSIONS
  The use of transfer factor in women with HPV showed resolution of genital lesions, without recurrences for at least one year after the treatment was ended.
authors.affiliation: Anexo Hospital Angeles Mocel, Ignacio Esteva 107 consultorio 206, MÈxico 11850 D.F. blancamorfin@hotmail.com.
authors.forename: Blanca María
authors.initials: BM
authors.lastname: Morfin-Maciel
authors.forename: Julieta Margarita
authors.initials: JM
authors.lastname: Sotelo-Ortiz
mesh_terms: D006801:Humans; D009364:Neoplasm Recurrence, Local; D030361:Papillomavirus Infections; D012307:Risk Factors; D014165:Transfer Factor; D002583:Uterine Cervical Neoplasms; D002578:Uterine Cervical Dysplasia
chemical_list: D014165:Transfer Factor